Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0CDYJL
ADC Name
MYTX-011
Synonyms
MYTX 011; MYTX-011; MYTX011
   Click to Show/Hide
Organization
Mythic Therapeutics, Inc.
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Lung cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
2
Antibody Name
pH-dependent antic-MET antibody
  Antibody Info 
Antigen Name
Hepatocyte growth factor receptor (MET)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Undisclosed
Combination Type
vedotin
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05652868
Phase 1
A phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate MYTX-011 in subjects with non-small cell lung cancer - kismet-01.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05652868  Clinical Status Phase 1
Clinical Description A phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate MYTX-011 in subjects with non-small cell lung cancer - kismet-01.
References
Ref 1 A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01, NCT05652868